BR112012022214A2 - métodos e composições para tratar doença de degos - Google Patents
métodos e composições para tratar doença de degosInfo
- Publication number
- BR112012022214A2 BR112012022214A2 BR112012022214A BR112012022214A BR112012022214A2 BR 112012022214 A2 BR112012022214 A2 BR 112012022214A2 BR 112012022214 A BR112012022214 A BR 112012022214A BR 112012022214 A BR112012022214 A BR 112012022214A BR 112012022214 A2 BR112012022214 A2 BR 112012022214A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- degum
- disease
- treating
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
Abstract
métodos e composições para tratar doença de degos. a presente descrição refere-se, inter alia, as composições contendo um inibido de complemento humano e/ou um inibidor de interferona alfa, e o uso das composições em métodos para tratar ou prevenir doença de degos em um indivíduo. em algumas modalidades, o inibidor é um anticorpo, ou fragmento de ligação de antígeno do mesmo, que liga-se a uma proteína de componente de complemento humano c5 ou a um fragmento biologicamente ativo de c5 tal como c5a tal como c5a ou c5b. em algumas modalidades, o inibidor é um anticorpo, ou um fragmento de ligação de antígeno do mesmo, que liga-se á interfona alfa ou a um receptor de interferona alfa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30939310P | 2010-03-01 | 2010-03-01 | |
| PCT/US2011/026602 WO2011109338A1 (en) | 2010-03-01 | 2011-03-01 | Methods and compositions for treating degos' disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012022214A2 true BR112012022214A2 (pt) | 2017-07-04 |
Family
ID=44542525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012022214A BR112012022214A2 (pt) | 2010-03-01 | 2011-03-01 | métodos e composições para tratar doença de degos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8999340B2 (pt) |
| EP (1) | EP2542255B1 (pt) |
| JP (3) | JP5852021B2 (pt) |
| KR (1) | KR20130009784A (pt) |
| CN (1) | CN102985106A (pt) |
| AU (1) | AU2011223866B2 (pt) |
| BR (1) | BR112012022214A2 (pt) |
| CA (1) | CA2791962A1 (pt) |
| ES (1) | ES2615732T3 (pt) |
| MX (1) | MX2012010116A (pt) |
| NZ (1) | NZ602219A (pt) |
| RU (2) | RU2015145543A (pt) |
| SG (1) | SG183541A1 (pt) |
| WO (1) | WO2011109338A1 (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
| WO2008044928A1 (en) | 2006-10-10 | 2008-04-17 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Complement inhibition for improved nerve regeneration |
| HUE029635T2 (en) | 2007-09-26 | 2017-03-28 | Chugai Pharmaceutical Co Ltd | A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR |
| TW202423982A (zh) | 2008-04-11 | 2024-06-16 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| BR112012022214A2 (pt) * | 2010-03-01 | 2017-07-04 | Alexion Pharma Inc | métodos e composições para tratar doença de degos |
| KR102568454B1 (ko) | 2010-11-30 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
| KR20210021101A (ko) | 2011-04-08 | 2021-02-24 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
| EP3511339A1 (en) | 2012-02-20 | 2019-07-17 | Swedish Orphan Biovitrum AB (Publ) | Polypeptides binding to human complement c5 |
| JP6538561B2 (ja) | 2012-10-25 | 2019-07-03 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 抗補体Ｃ１ｓ抗体とそれらの用途 |
| GB2509260B (en) | 2012-11-02 | 2016-05-04 | True North Therapeutics Inc | Anti-complement C1s antibodies and uses thereof |
| WO2014110438A1 (en) * | 2013-01-11 | 2014-07-17 | Alexion Pharmaceuticals, Inc. | Compounds and methods related to the c5d domain of complement component c5 |
| KR101638931B1 (ko) | 2013-01-31 | 2016-07-12 | 서울대학교산학협력단 | 보체 관련 질환의 예방 및 치료를 위한 ｃ5 항체 및 방법 |
| PE20160046A1 (es) | 2013-03-14 | 2016-02-14 | Alnylam Pharmaceuticals Inc | COMPOSICION DE ARNi CONTRA EL COMPONENTE DE C5 DEL COMPLEMENTO Y METODOS PARA SU USO |
| ES2768648T3 (es) * | 2013-03-29 | 2020-06-23 | Alexion Pharma Inc | Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento |
| WO2015039126A1 (en) | 2013-09-16 | 2015-03-19 | Children hospital medical center | Compositions and methods for treatment of hsct-associated thrombotic microangiopathy |
| CN105683219B (zh) | 2013-10-17 | 2020-07-14 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化有关的病况的方法 |
| WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| US10544209B2 (en) | 2014-10-15 | 2020-01-28 | Alexion Pharmaceuticals, Inc. | Methods of replicating a large scale eculizumab production cell culture |
| EP3207058A1 (en) * | 2014-10-15 | 2017-08-23 | Alexion Pharmaceuticals, Inc. | Methods of culturing a cell |
| MY183415A (en) * | 2014-12-19 | 2021-02-18 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| PT3280440T (pt) | 2015-04-06 | 2023-02-14 | Bioverativ Usa Inc | Anticorpos anti-c1s humanizados e métodos de utilização destes |
| EP3307318A4 (en) | 2015-06-09 | 2019-01-16 | Children's Hospital Medical Center | DOSAGE ALGORITHM FOR COMPLEMENT INHIBITOR |
| CA2997745A1 (en) | 2015-09-14 | 2017-03-23 | Children's Hospital Medical Center | Methods and compositions for treatment of gaucher disease via modulation of c5a receptor |
| DK3390442T5 (da) | 2015-12-18 | 2024-09-23 | Chugai Pharmaceutical Co Ltd | Anti-C5 antistoffer og fremgangsmåde til anvendelse deraf |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| TWI831965B (zh) | 2016-08-05 | 2024-02-11 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
| US12037389B2 (en) * | 2017-12-01 | 2024-07-16 | Children's Hospital Medical Center | Compositions for interferon blockade and methods of using same |
| MA51147A (fr) | 2017-12-13 | 2021-03-24 | Regeneron Pharma | Associations d'anticorps anti-c5 et utilisations associées |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0563487A1 (en) * | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| CN103145840A (zh) * | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
| US20070292421A1 (en) * | 2005-07-28 | 2007-12-20 | Feinberg Bruce B | Method for treating preeclampsia |
| NZ568204A (en) * | 2005-10-13 | 2012-01-12 | Human Genome Sciences Inc | Methods and compositions for use in treatment of patients with autoantibody positive diseases |
| US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| US20110130544A1 (en) * | 2007-03-30 | 2011-06-02 | Medimmune, Llc | Antibodies with decreased deamidation profiles |
| KR101651678B1 (ko) * | 2007-05-21 | 2016-08-26 | 제넨테크, 인크. | 루푸스를 확인 및 치료하기 위한 방법 및 조성물 |
| WO2009149306A2 (en) | 2008-06-04 | 2009-12-10 | Incode Biopharmaceutics, Inc. | Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds |
| LT2894165T (lt) * | 2008-11-10 | 2023-03-10 | Alexion Pharmaceuticals, Inc. | Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui |
| NZ597259A (en) * | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| BR112012022214A2 (pt) * | 2010-03-01 | 2017-07-04 | Alexion Pharma Inc | métodos e composições para tratar doença de degos |
-
2011
- 2011-03-01 BR BR112012022214A patent/BR112012022214A2/pt not_active IP Right Cessation
- 2011-03-01 CA CA2791962A patent/CA2791962A1/en not_active Abandoned
- 2011-03-01 NZ NZ602219A patent/NZ602219A/en not_active IP Right Cessation
- 2011-03-01 RU RU2015145543A patent/RU2015145543A/ru unknown
- 2011-03-01 EP EP11751164.2A patent/EP2542255B1/en active Active
- 2011-03-01 CN CN2011800220097A patent/CN102985106A/zh active Pending
- 2011-03-01 KR KR1020127024302A patent/KR20130009784A/ko not_active Application Discontinuation
- 2011-03-01 MX MX2012010116A patent/MX2012010116A/es active IP Right Grant
- 2011-03-01 SG SG2012064150A patent/SG183541A1/en unknown
- 2011-03-01 ES ES11751164.2T patent/ES2615732T3/es active Active
- 2011-03-01 AU AU2011223866A patent/AU2011223866B2/en not_active Ceased
- 2011-03-01 RU RU2012141556/15A patent/RU2570390C2/ru not_active IP Right Cessation
- 2011-03-01 US US13/582,018 patent/US8999340B2/en active Active
- 2011-03-01 JP JP2012556156A patent/JP5852021B2/ja active Active
- 2011-03-01 WO PCT/US2011/026602 patent/WO2011109338A1/en active Application Filing
-
2015
- 2015-03-04 US US14/638,636 patent/US20150174243A1/en not_active Abandoned
- 2015-11-04 JP JP2015216557A patent/JP2016026217A/ja not_active Withdrawn
- 2015-11-04 JP JP2015216556A patent/JP2016026216A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN102985106A (zh) | 2013-03-20 |
| US8999340B2 (en) | 2015-04-07 |
| RU2570390C2 (ru) | 2015-12-10 |
| SG183541A1 (en) | 2012-10-30 |
| CA2791962A1 (en) | 2011-09-09 |
| AU2011223866A1 (en) | 2012-09-27 |
| US20150174243A1 (en) | 2015-06-25 |
| AU2011223866B2 (en) | 2015-05-21 |
| EP2542255B1 (en) | 2016-11-16 |
| JP2013521294A (ja) | 2013-06-10 |
| EP2542255A4 (en) | 2013-07-31 |
| KR20130009784A (ko) | 2013-01-23 |
| US20130064820A1 (en) | 2013-03-14 |
| JP2016026216A (ja) | 2016-02-12 |
| RU2015145543A3 (pt) | 2019-01-11 |
| RU2015145543A (ru) | 2019-01-11 |
| WO2011109338A1 (en) | 2011-09-09 |
| JP5852021B2 (ja) | 2016-02-03 |
| MX2012010116A (es) | 2013-02-26 |
| ES2615732T3 (es) | 2017-06-08 |
| NZ602219A (en) | 2014-10-31 |
| JP2016026217A (ja) | 2016-02-12 |
| RU2012141556A (ru) | 2014-04-10 |
| EP2542255A1 (en) | 2013-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012022214A2 (pt) | métodos e composições para tratar doença de degos | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| UY32341A (es) | Proteínas de unión antígeno novedosas | |
| EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
| BR112012018951C8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| BR112013021863A2 (pt) | anticorpos anti-receptor il-6 e métodos de uso | |
| ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| BR112016025009A2 (pt) | anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| MX358224B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado. | |
| BR112013007314A2 (pt) | anticorpos anti-cd48 e seus usos | |
| MX358013B (es) | Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3. | |
| BR112014007382A2 (pt) | anticorpos anti-erbb3 e seus usos | |
| UA109658C2 (xx) | Антитіло проти cgrp | |
| BR112012019098B8 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica | |
| MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
| AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| NZ604510A (en) | Dilutable biocidal compositions and methods of use | |
| BR112012020101A2 (pt) | método diagnósticos e terapêuticos usando anticorpos anti-cd200. | |
| UY33421A (es) | Proteinas de union al antígeno humanizados | |
| CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
| BR112018072681A2 (pt) | anticorpos anti-il-1r3 humanizados | |
| CL2013001138A1 (es) | Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición. | |
| BR112014006587A8 (pt) | Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |